Warren Ferguson, MD, a correctional health expert at UMass Medical School, talked to The New York Times about the high cost of treating hepatitis C-infected inmates with the expensive new drug Sovaldi.
“Every state is talking about this,” said Dr. Ferguson, professor and vice chair of family medicine & community health, and director of academic programs for health and justice programs within the Commonwealth Medicine division.
In the Aug. 7 article, Ferguson explained that it would costs states millions more than they budget for total health care to treat every inmate who would benefit from hepatitis C drugs.
Read the full story: Why the Hepatitis Cure Sovaldi Is a Budgetary Disaster for Prisons
